Journal of Lipid Research (May 2005)
Alcohol intake modulates the genetic association between HDL cholesterol and the PPARγ2 Pro12Ala polymorphism
- Stefan-Martin Brand-Herrmann,
- Tatiana Kuznetsova,
- Andreas Wiechert,
- Katarzyna Stolarz,
- Valerie Tikhonoff,
- Klaus Schmidt-Petersen,
- Ralph Telgmann,
- Edoardo Casiglia,
- Ji-Guang Wang,
- Lutgarde Thijs,
- Jan A. Staessen,
- Eva Brand
Affiliations
- Stefan-Martin Brand-Herrmann
- Leibniz Institute for Arteriosclerosis Research, Department of Molecular Genetics of Cardiovascular Disease, University of Muenster, Muenster, Germany; Study Coordinating Center, Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven, Leuven, Belgium; Institute of Internal Medicine, Novosibirsk, Russian Federation; Charité, University Medicine Berlin, Campus Benjamin Franklin, Department of Internal Medicine, Division of Endocrinology and Nephrology, Berlin, Germany; First Cardiac Department, Jagiellonian University, Cracow, Poland; Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy; Department of Internal Medicine D, Nephrology and Hypertension, University Clinic of Muenster, Muenster, Germany
- Tatiana Kuznetsova
- Leibniz Institute for Arteriosclerosis Research, Department of Molecular Genetics of Cardiovascular Disease, University of Muenster, Muenster, Germany; Study Coordinating Center, Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven, Leuven, Belgium; Institute of Internal Medicine, Novosibirsk, Russian Federation; Charité, University Medicine Berlin, Campus Benjamin Franklin, Department of Internal Medicine, Division of Endocrinology and Nephrology, Berlin, Germany; First Cardiac Department, Jagiellonian University, Cracow, Poland; Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy; Department of Internal Medicine D, Nephrology and Hypertension, University Clinic of Muenster, Muenster, Germany
- Andreas Wiechert
- Leibniz Institute for Arteriosclerosis Research, Department of Molecular Genetics of Cardiovascular Disease, University of Muenster, Muenster, Germany; Study Coordinating Center, Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven, Leuven, Belgium; Institute of Internal Medicine, Novosibirsk, Russian Federation; Charité, University Medicine Berlin, Campus Benjamin Franklin, Department of Internal Medicine, Division of Endocrinology and Nephrology, Berlin, Germany; First Cardiac Department, Jagiellonian University, Cracow, Poland; Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy; Department of Internal Medicine D, Nephrology and Hypertension, University Clinic of Muenster, Muenster, Germany
- Katarzyna Stolarz
- Leibniz Institute for Arteriosclerosis Research, Department of Molecular Genetics of Cardiovascular Disease, University of Muenster, Muenster, Germany; Study Coordinating Center, Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven, Leuven, Belgium; Institute of Internal Medicine, Novosibirsk, Russian Federation; Charité, University Medicine Berlin, Campus Benjamin Franklin, Department of Internal Medicine, Division of Endocrinology and Nephrology, Berlin, Germany; First Cardiac Department, Jagiellonian University, Cracow, Poland; Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy; Department of Internal Medicine D, Nephrology and Hypertension, University Clinic of Muenster, Muenster, Germany
- Valerie Tikhonoff
- Leibniz Institute for Arteriosclerosis Research, Department of Molecular Genetics of Cardiovascular Disease, University of Muenster, Muenster, Germany; Study Coordinating Center, Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven, Leuven, Belgium; Institute of Internal Medicine, Novosibirsk, Russian Federation; Charité, University Medicine Berlin, Campus Benjamin Franklin, Department of Internal Medicine, Division of Endocrinology and Nephrology, Berlin, Germany; First Cardiac Department, Jagiellonian University, Cracow, Poland; Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy; Department of Internal Medicine D, Nephrology and Hypertension, University Clinic of Muenster, Muenster, Germany
- Klaus Schmidt-Petersen
- Leibniz Institute for Arteriosclerosis Research, Department of Molecular Genetics of Cardiovascular Disease, University of Muenster, Muenster, Germany; Study Coordinating Center, Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven, Leuven, Belgium; Institute of Internal Medicine, Novosibirsk, Russian Federation; Charité, University Medicine Berlin, Campus Benjamin Franklin, Department of Internal Medicine, Division of Endocrinology and Nephrology, Berlin, Germany; First Cardiac Department, Jagiellonian University, Cracow, Poland; Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy; Department of Internal Medicine D, Nephrology and Hypertension, University Clinic of Muenster, Muenster, Germany
- Ralph Telgmann
- Leibniz Institute for Arteriosclerosis Research, Department of Molecular Genetics of Cardiovascular Disease, University of Muenster, Muenster, Germany; Study Coordinating Center, Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven, Leuven, Belgium; Institute of Internal Medicine, Novosibirsk, Russian Federation; Charité, University Medicine Berlin, Campus Benjamin Franklin, Department of Internal Medicine, Division of Endocrinology and Nephrology, Berlin, Germany; First Cardiac Department, Jagiellonian University, Cracow, Poland; Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy; Department of Internal Medicine D, Nephrology and Hypertension, University Clinic of Muenster, Muenster, Germany
- Edoardo Casiglia
- Leibniz Institute for Arteriosclerosis Research, Department of Molecular Genetics of Cardiovascular Disease, University of Muenster, Muenster, Germany; Study Coordinating Center, Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven, Leuven, Belgium; Institute of Internal Medicine, Novosibirsk, Russian Federation; Charité, University Medicine Berlin, Campus Benjamin Franklin, Department of Internal Medicine, Division of Endocrinology and Nephrology, Berlin, Germany; First Cardiac Department, Jagiellonian University, Cracow, Poland; Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy; Department of Internal Medicine D, Nephrology and Hypertension, University Clinic of Muenster, Muenster, Germany
- Ji-Guang Wang
- Leibniz Institute for Arteriosclerosis Research, Department of Molecular Genetics of Cardiovascular Disease, University of Muenster, Muenster, Germany; Study Coordinating Center, Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven, Leuven, Belgium; Institute of Internal Medicine, Novosibirsk, Russian Federation; Charité, University Medicine Berlin, Campus Benjamin Franklin, Department of Internal Medicine, Division of Endocrinology and Nephrology, Berlin, Germany; First Cardiac Department, Jagiellonian University, Cracow, Poland; Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy; Department of Internal Medicine D, Nephrology and Hypertension, University Clinic of Muenster, Muenster, Germany
- Lutgarde Thijs
- Leibniz Institute for Arteriosclerosis Research, Department of Molecular Genetics of Cardiovascular Disease, University of Muenster, Muenster, Germany; Study Coordinating Center, Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven, Leuven, Belgium; Institute of Internal Medicine, Novosibirsk, Russian Federation; Charité, University Medicine Berlin, Campus Benjamin Franklin, Department of Internal Medicine, Division of Endocrinology and Nephrology, Berlin, Germany; First Cardiac Department, Jagiellonian University, Cracow, Poland; Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy; Department of Internal Medicine D, Nephrology and Hypertension, University Clinic of Muenster, Muenster, Germany
- Jan A. Staessen
- Leibniz Institute for Arteriosclerosis Research, Department of Molecular Genetics of Cardiovascular Disease, University of Muenster, Muenster, Germany; Study Coordinating Center, Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven, Leuven, Belgium; Institute of Internal Medicine, Novosibirsk, Russian Federation; Charité, University Medicine Berlin, Campus Benjamin Franklin, Department of Internal Medicine, Division of Endocrinology and Nephrology, Berlin, Germany; First Cardiac Department, Jagiellonian University, Cracow, Poland; Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy; Department of Internal Medicine D, Nephrology and Hypertension, University Clinic of Muenster, Muenster, Germany
- Eva Brand
- Leibniz Institute for Arteriosclerosis Research, Department of Molecular Genetics of Cardiovascular Disease, University of Muenster, Muenster, Germany; Study Coordinating Center, Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven, Leuven, Belgium; Institute of Internal Medicine, Novosibirsk, Russian Federation; Charité, University Medicine Berlin, Campus Benjamin Franklin, Department of Internal Medicine, Division of Endocrinology and Nephrology, Berlin, Germany; First Cardiac Department, Jagiellonian University, Cracow, Poland; Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy; Department of Internal Medicine D, Nephrology and Hypertension, University Clinic of Muenster, Muenster, Germany
- Journal volume & issue
-
Vol. 46,
no. 5
pp. 913 – 919
Abstract
The peroxisome proliferator-activated receptor γ (PPARγ) Pro12Ala polymorphism affects plasma lipids, but to what extent alcohol intake interferes with this association remains unknown. We randomly recruited 251 nuclear families (433 parents and 493 offspring) in the framework of the European Project on Genes in Hypertension study and genotyped 926 participants in whom all serum lipid variables and information on alcohol consumption were available for PPARγ2 Pro12Ala. Genotype-phenotype relations were assessed using generalized estimating equations (GEE) and a quantitative transmission disequilibrium test (QTDT). The Ala12 allele was more frequent in Novosibirsk (0.17) than in Cracow (0.12) and Mirano (0.11) (P < 0.01). Using GEE (P = 0.03) or QTDT (P = 0.007), Italian offspring carrying the Ala12 allele had higher serum HDL cholesterol than noncarriers. HDL cholesterol levels were on average 0.086 mmol/l (P = 0.001) higher in drinkers than in nondrinkers. Compared with Pro12 homozygotes, Ala12 allele carriers consuming alcohol had higher serum total and HDL cholesterol, with the opposite trend occurring in nondrinkers. This genotype-alcohol interaction was independent of the type of alcoholic beverage and more pronounced in moderate than in heavy drinkers.We conclude that alcohol intake modulates the relation between the PPARγ2 Pro12Ala and HDL cholesterol level and that, therefore, the Pro12Ala polymorphism, pending confirmation of our findings, might affect cardiovascular prognosis.
